Latest adjuvant therapy Stories
Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- Genomic
Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan.
An analysis by ECOG-ACRIN researchers shows that TILs are a prognostic factor in women with triple negative breast cancer. San Antonio, TX (PRWEB) December 13,
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes.
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14.
Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology.
Nearly 80 percent of women who contacted a patient assistance program had some or all of their needs met, compared with only 35 percent of those who did not New
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone.
- A serpent whose bite was fabled to produce intense thirst.